Checkpoint Therapeutics, Inc. (CKPT)
Stock Price:
$2.10 USD
-0.05 (-2.33%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
115.62M |
| Revenue (ttm) |
1.32M |
| Net Income (ttm) |
-21.96M |
| Shares Out |
53.04M |
| EPS (ttm) |
-0.49 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$2.10 |
| Previous Close |
$2.15 |
| Change ($) |
-0.05 |
| Change (%) |
-2.33% |
| Day's Open |
- |
| Day's Range |
2.10 - 2.21 |
| Day's Volume |
731,635 |
| 52-Week Range |
1.05 - 3.34 |
More Stats
| Market Cap |
115.62M |
| Enterprise Value |
93.70M |
| Earnings Date (est) |
Oct 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
53.04M |
| Float |
45.33M |
| EPS (basic) |
-0.52 |
| EPS (diluted) |
-0.49 |
| FCF / Share |
-0.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
896,320 |
| Short Ratio |
3.17 |
| Short % of Float |
2.25% |
| Beta |
2.09 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
87.66 |
| PB Ratio |
9.22 |
| Revenue |
1.32M |
| Operating Income |
-22.11M |
| Net Income |
-21.96M |
| Free Cash Flow |
-14.92M |
| Net Cash |
21.92M |
| Net Cash / Share |
0.40 |
| Gross Margin |
-1,335.63% |
| Operating Margin |
-1,675.97% |
| Profit Margin |
-1,664.70% |
| FCF Margin |
-1,130.86% |
| ROA |
-72.89% |
| ROE |
-197.97% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.33*
(582.38% upside)
Low
8.00
Current: $2.10
High
20.00
Target: 14.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 1.71 | 3.51 | 1.73 | 2.57 | 0.59 |
| Revenue Growth | -51.28% | 103.25% | -32.88% | 335.59% | - |
| Gross Profit | 1.71 | 3.51 | 1.73 | 2.57 | 0.59 |
| Operating Income | -24.85 | -36.74 | -22.78 | -22.16 | -13.22 |
| Net Income | -24.71 | -36.37 | -22.68 | -22.46 | -13.89 |
| Shares Outstanding | 35.30 | 28.55 | 22.62 | 21.54 | 9.86 |
| Earnings Per Share | -0.70 | -1.27 | -1.00 | -1.04 | -1.41 |
| Operating Cash Flow | -21.37 | -25.81 | -15.46 | -9.95 | -1.11 |
| Free Cash Flow | -21.37 | -25.81 | -15.46 | -9.95 | -1.11 |
| Cash & Equivalents | 26.08 | 22.00 | 19.23 | 35.09 | 50.42 |
| Total Debt | - | - | - | - | 2.47 |
| Net Cash / Debt | 26.08 | 22.00 | 19.23 | 35.09 | 47.95 |
| Assets | 26.97 | 24.90 | 21.41 | 35.98 | 50.65 |
| Liabilities | 8.12 | 13.09 | 6.37 | 3.67 | 4.26 |
| Book Value | 18.85 | 11.81 | 15.04 | 32.31 | 46.40 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Checkpoint Therapeutics, Inc. |
| Country |
United States |
| Employees |
8 |
| CEO |
James F. Oliviero |
Stock Information
| Ticker Symbol |
CKPT |
| Stock Exchange |
NASDAQ |
| Unique Identifier |
NASDAQ: CKPT |
| IPO Date |
June 26, 2017 |
Description
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.